article thumbnail

Regeneron and Lilly post new data backing COVID antibody cocktails

pharmaphorum

Regeneron is considering an emergency filing for its antibody cocktail REGEN-COV to protect people against COVID-19 after early trial results showed it conferred 100% protection against symptomatic infection. The post Regeneron and Lilly post new data backing COVID antibody cocktails appeared first on.

article thumbnail

Chasing Regeneron, AZ starts trials of its COVID-19 antibody cocktail

pharmaphorum

The first patients have been dosed in a trial of two AstraZeneca antibodies, collectively known as AZD7442, that are being developed to both treat and prevent coronavirus infections. The phase 1 trialfunded by the US government – will take place in the UK and will test the safety of AZD7442 and its pharmacokinetic profile.